According to the immunohistochemical results from our clinical samples, both CD163 and CD68 expression was positively correlated with VM enhancement, suggesting that the increased recruitment of TAMs was associated with VM enhancement in RCC tumor tissues (Fig. 1I and D). Here, CD163 is linked to renal cell carcinoma.